← Back to Search

Polymer Scaffold

Neuro-Spinal Scaffold for Spinal Cord Injury

N/A
Waitlist Available
Research Sponsored by InVivo Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months post-implantation
Awards & highlights

Study Summary

This trial will evaluate the safety and probable benefit of a Scaffold in subjects with a certain type of spinal cord injury.

Who is the study for?
This trial is for individuals aged 16-70 with a recent (within 7 days) traumatic spinal cord injury at T2-T12 levels, classified as AIS A. They must require and be suitable for open spine surgery, have a stable health condition, and consent to participate. Excluded are those with incomplete SCI, multiple injuries, significant brain injury or coma, pre-existing neurological or respiratory diseases unrelated to the injury, immune deficiencies like HIV/AIDS, substance abuse issues, pregnancy or unwillingness to use birth control post-surgery.Check my eligibility
What is being tested?
The INSPIRE Study tests the safety and potential benefit of implanting a Neuro-Spinal Scaffold in patients with thoracic AIS A traumatic spinal cord injuries. The Scaffold is made from poly(lactic-co-glycolic acid)-b-poly(L-lysine). This single-arm study does not randomize participants but evaluates all who receive the intervention.See study design
What are the potential side effects?
Potential side effects may include reactions related to scaffold implantation such as inflammation at the site of surgery, infection risks due to compromised immunity around the injured area and general surgical risks including bleeding and adverse reactions to anesthesia.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months post-implantation
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months post-implantation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Patients With Improvement in AIS Grade of One or More Levels
Secondary outcome measures
Change From Baseline in ISNCSCI Total Motor Score
Number of Participants Stratified by Change From Baseline in ISNCSCI Sensory Light Touch Score
Number of Participants Stratified by Change From Baseline in ISNCSCI Sensory Pin Prick Score
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Neuro-Spinal ScaffoldExperimental Treatment1 Intervention
Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery

Find a Location

Who is running the clinical trial?

InVivo TherapeuticsLead Sponsor
2 Previous Clinical Trials
20 Total Patients Enrolled
Richard Toselli, MDStudy DirectorInVivo Therapeutics Corporation
1 Previous Clinical Trials

Media Library

Neuro-Spinal Scaffold (Polymer Scaffold) Clinical Trial Eligibility Overview. Trial Name: NCT02138110 — N/A
Spinal Cord Injury Research Study Groups: Neuro-Spinal Scaffold
Spinal Cord Injury Clinical Trial 2023: Neuro-Spinal Scaffold Highlights & Side Effects. Trial Name: NCT02138110 — N/A
Neuro-Spinal Scaffold (Polymer Scaffold) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02138110 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are any individuals beyond the age of twenty-five being considered for enrollment in this clinical trial?

"This research is looking for patients who are between 16 and 70 years old."

Answered by AI

Are individuals currently being accepted for enrollment in this test?

"Unfortunately, the clinical trial has ceased recruiting. Initially posted on October 13th 2014 and last updated November 19th 2021, this study is no longer taking patients. Nevertheless, there are 904 other trials in need of participants at present."

Answered by AI

Is this clinical trial being administered in more than one location within the state?

"This clinical trial has 8 recruitment sites, including but not limited to Oregon Health & Science University in Portland, Allegheny General Hospital in Pittsburgh and Vidant Medical Center in Greenville."

Answered by AI

What criteria must be met for someone to participate in this medical investigation?

"This clinical trial is recruiting 20 individuals aged 16 to 70 with non-penetrating spinal cord injuries that measure at least 4 millimeters in diameter. Qualified medical professionals must confirm the AIS A classification of traumatic injury, which occurred no longer than seven days prior. Furthermore, hemodynamic stability and eligibility for open spine surgery are necessary criteria before informed consent can be obtained from participants."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Met criteria
What site did they apply to?
Carolina NeuroSurgery and Spine Associates/Carolinas Rehabilitation
Vidant Medical Center
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I am a 53-year-old white male. On September 18, 2023 I had an accident, I fell from a tree I was working in, fractured my back in 2 places, and sustained a significant spinal cord injury from a bone fragment compressing on my spinal cord. In addition, I broke 9 ribs and punctured a lung. I very much want to regain the ability to walk. I do have some movement in my legs and some sensation of feeling in my legs. My upper body is strong and was not affected by the injury. I live 10 miles south of Winston-Salem NC. I am self employed so my schedule can be flexible. Additionally I am well educated; I have one masters and two bachelor degrees. I am very comfortable in a clinical setting and I have an understanding of testing. I am willing to turn over all medical information from other providers if I am selected for a trial. I look forward to hearing from you and discussing the next steps.
PatientReceived 1 prior treatment
Recent research and studies
~2 spots leftby Apr 2025